Strengthening research, technological development and innovation
Promoting innovation capacities for a more competitive area
The overall project objective is to bring together, share and improve the therapeutic methodologies and diagnostic possibilities of rare diseases in children. At the time being, the two clinical reference centers of the pediatric age are working independently. It is intended to transfer specialist knowledge from clinical and research centers to important companies in the "Health" sector, in the Programme Area.
The so-called "rare diseases" do not receive adequate study and research attention from the scientific community and pharmaceutical industry. Many of these diseases occur in children and require continuous diagnostic and therapeutic efforts to improve the quality of life of affected children and to minimize
the socio-economic impact on families and health system. In the Programme Area already exist consolidated clinical and scientific skills, especially in the cross-border axis between the IRCCS Burlo Garofolo of Trieste and the Pediatric clinic of the University of Ljubljana who already cooperate on research on some rare diseases such as immune-mediated inflammatory diseases. However, the following are still missing: a) patient-centered diagnostic methods capable of defining specific individual pathological profiles and targeted treatments; b) a widespread knowledge throughout the territory on diagnostic and therapeutic possibilities in this sector; c) efficient tools for knowledge /research results sharing, especially towards general practitioners, hospital doctors and patient associations. The project CATTEDRA intends to address these shortcomings by bringing together clinical centers, research centers and companies.
Two are the results of the project. The first is the transfer, integration and sharing of diagnostic and therapeutic data on therapies. To achieve this result, cooperation between "scientific" partners and "business" partners is foreseen in line with output indicator for IP 1.b. This result will not only strengthen cooperation between two key pediatric bodies but will also provide data and guidelines on common therapeutic protocols useful to hospitals/doctors/healthcare professionals involved with children affected by immune-mediated diseases.
The second result is a feasibility study of 4 innovative diagnostic tests developed putting together the experiences of Burlo and UCKLJ altogether with the technical support by CO BIK. Also for this result, close collaboration public / private partners is foreseen to transfer useful knowledge from clinical /research centers to companies, contributing to the programme output indicator CO26. The feasibility study of new shared diagnostic tests will allow to lay the basis for new cross-border collaborations but also to stimulate Italian and Slovene companies in the biomedical sector to cooperate with research bodies, in particular within the diagnostic sector in vitro.
Lead Partner
Project partner 1
Project partner 2
Project partner 3
Project partner 4
 | POSTER CATTEDRA 70x100 cm - ITA 70x100_CATTEDRA_ITA.pdf ( 323 bytes, published on 8 January, 2021 - 09:54 ) |
| POSTER CATTEDRA A3 - ITA A3_CATTEDRA_ITA.pdf ( 243 bytes, published on 30 April, 2021 - 12:28 ) |
KEY PROJECT OBJECTIVES
The overall project objective is to bring together, share and improve the therapeutic methodologies and diagnostic possibilities of rare diseases in children. At the time being, the two clinical reference centers of the pediatric age are working independently. It is intended to transfer specialist knowledge from clinical and research centers to important companies in the "Health" sector, in the Programme Area.
CURRENT STATUS OF IMPLEMENTATION
The Project started on 1/1/2020.
Operation co-funded by the European Regional Development Fund
